论文部分内容阅读
目的观察大剂量化疗、自体外周血干细胞移植、生物治疗、长间歇维持化疗序贯治疗急性白血病的临床疗效。方法自2001年3月~2009年12月对第三军医大学新桥医院69名急性白血病患者进行大剂量化疗、自体外周血干细胞移植、白介素-2(IL-2)生物治疗、长间歇维持化疗序贯治疗,其中,急性淋巴细胞白血病(ALL)40例,急性髓细胞白血病(AML)29例,观察临床疗效和并发症。结果除1例ALL外,68名患者移植后造血功能均快速重建。急性淋巴细胞白血病首次完全缓解(ALL-CR1)25例,其中无病存活17例,带病存活2例,死亡6例,急性淋巴细胞白血病再次完全缓解(ALL-CR2)15例,其中无病存活3例,带病存活3例,死亡9例;急性髓细胞白血病首次完全缓解(AML-CR1)17,其中无病存活10例,带病存活2例,死亡5例,急性髓细胞白血病再次完全缓解(AML-CR2)12例,其中无病存活5例,带病存活1例,死亡6例。结论该序贯疗法治疗急性白血病安全有效,CR1患者较CR2患者疗效更好。
Objective To observe the clinical efficacy of high-dose chemotherapy, autologous peripheral blood stem cell transplantation, biological therapy, and long-term intermittent maintenance chemotherapy in the treatment of acute leukemia. Methods From March 2001 to December 2009, 69 patients with acute leukemia at Xinqiao Hospital of the Third Military Medical University underwent high-dose chemotherapy, autologous peripheral blood stem cell transplantation, interleukin-2 (IL-2) biotherapy and long-term maintenance chemotherapy Sequential treatment, of which 40 cases of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) in 29 cases, to observe the clinical efficacy and complications. Results All the 68 patients had rapid hematopoietic reconstitution except one case of ALL. There were 25 patients with acute lymphoblastic leukemia for the first time (ALL-CR1), of which 17 were disease-free, 2 were sick, 6 were dead, 15 were ALL-CR2 (ALL-CR2) Survival in 3 cases, 3 cases with disease survived, 9 died; acute myeloid leukemia complete remission for the first time (AML-CR1) 17, of which 10 cases of disease-free survival, sick in 2 cases, 5 cases of death, acute myeloid leukemia again Complete remission (AML-CR2) in 12 cases, including disease-free survival in 5 cases, 1 case of disease survived, 6 died. Conclusions This sequential therapy is safe and effective in the treatment of acute leukemia. CR1 patients are more effective than CR2 patients.